Literature DB >> 21670772

Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin.

Paloma Muñoz de Rueda1, Miguel-Ángel López-Nevot, Pablo Sáenz-López, Jorge Casado, Antonia Martín-Casares, Pablo Palomares, Rosa Quiles, Ana Gila, Manuel Romero-Gómez, Esther-José Pavón, José-Antonio Muñoz, Angel Carazo, Paloma Sanz-Cameno, Ricardo Moreno-Otero, Moisés Diago, Josefa León, Angeles Ruiz-Extremera, Javier Salmerón.   

Abstract

OBJECTIVES: Viral factors are considered the best predictors of response to treatment for chronic hepatitis C (CHC), but genetic factors are known to have an important role in this respect. This paper investigates the relationships among the host genetic factors HLA and IL28B, viral factors, and the outcome of combination therapy.
METHODS: A multicenter retrospective cohort of 428 previously untreated CHC patients was treated with pegylated interferon/ribavirin (pegIFN/RBV) for 48 weeks. In all, 378 (88%) of these patients were genotype 1 or 4, and 50 (12%) were genotype 2 or 3.
RESULTS: Multivariate logistic regression showed the rs12979860 CC genotype (adjusted odds ratio (aOR)=4.3, 95% confidence interval (95% CI): 2.6-7), the HLA-DQB1*0301 allele (aOR=2.08, 95% CI: 1.2-3.5) and age, viral genotype, and viral load levels to be significantly associated with sustained virological response (SVR). When the variable rs12979860 was eliminated, the area under the receiver operating characteristic (ROC) curve (AUC) decreased significantly (0.76 vs. 0.69; P=0.03). AUC values derived from viral factors were lower than those corresponding to host genetic factors (0.67 vs. 0.72, respectively; P=0.04). The HLA-DQB1*0301 and A*0201 alleles were associated with rs12979860 CC genotype and SVR (P<0.0001).
CONCLUSIONS: The HLA-DQB1*0301 allele and IL28B genotype are factors that are associated independently with SVR. There is a synergism between the HLA-DQB1*0301 and HLA-A*0201 alleles with polymorphism rs12979860 CC, which increases the SVR rate. IL28B genotype is the best predictor of SVR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670772     DOI: 10.1038/ajg.2011.82

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

Review 1.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

Review 2.  Association between vitamin D and hepatitis C virus infection: a meta-analysis.

Authors:  Livia Melo Villar; José Antonio Del Campo; Isidora Ranchal; Elisabeth Lampe; Manuel Romero-Gomez
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

Review 3.  [Genetic susceptibility to infections].

Authors:  S J Ott; S Schreiber
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

Review 4.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

5.  Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b.

Authors:  Meng Wang; Yi Zhang; Zhiqin Li; Hongyu Zhang; Zhen Zhang; Dongli Yue; Rong Zhou; Xiaogang Li; Shuhuan Wu; Jiansheng Li
Journal:  Int J Clin Exp Med       Date:  2015-05-15

6.  A novel polymorphism near HLA class II region is associated with spontaneous clearance of HCV and response to interferon treatment in Chinese patients.

Authors:  Yin Xu; Peng Huang; Ming Yue; Jing Su; Hongbo Chen; Mingzhu Chen; Jie Wang; Jun Li; Zhihang Peng; Yun Zhang; Rongbin Yu
Journal:  J Hum Genet       Date:  2015-12-03       Impact factor: 3.172

7.  IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.

Authors:  A S Rangnekar; R J Fontana
Journal:  J Viral Hepat       Date:  2013-01-07       Impact factor: 3.728

Review 8.  IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.

Authors:  Christoph T Berger; Arthur Y Kim
Journal:  Infect Dis Clin North Am       Date:  2012-12       Impact factor: 5.982

9.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

10.  Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4.

Authors:  Olfat Shaker; Heba Bassiony; Maissa El Raziky; Samer S El-Kamary; Gamal Esmat; Akmal M El-Ghor; Mona M Mohamed
Journal:  Mediators Inflamm       Date:  2013-03-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.